Adial Pharmaceuticals Delays Shareholder Meeting to Oct. 26 Pending Nasdaq Approval

Adial Pharmaceuticals further adjourned its 2026 annual shareholder meeting to October 26 at 8:30 a.m. Eastern Time, pending Nasdaq listing approval. Voting remains open on four proposals postponed again on October 15; the meeting will reconvene at its Charlottesville, Virginia, offices. The August 17 record date remains unchanged; previously submitted proxies remain valid unless shareholders wish to change their votes. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adial Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-110349), on October 16, 2026, and is solely responsible for the information contained therein. (C)